Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 9/20 | 0.65 |
| ▸ | MAPT | P10636 | 10/20 | 0.50 |
| ▸ | MEN1 | O00255 | 7/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 2/20 | 0.45 |
| ▸ | PLEC | Q15149 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MST1R | Q04912 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28716665 | 1.00 | GAA (0.65) | GAAMAPTMEN1KMT2AALDH1A1 | |
| Tyrosine SCHEMBL11422737 | 0.77 | SLC7A5 (0.60) | SLC7A5 | |
| D-Phenylalanine SCHEMBL11422526 | 0.77 | SLC7A5 (0.58) | GAASLC1A3SLC1A2SLC1A1SLC7A5 | |
| SCHEMBL854529 | 0.74 | SLC7A5 (0.42) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL854528 | 0.74 | SLC7A5 (0.42) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL22689686 | 0.73 | SLC7A5 (0.56) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL21083181 | 0.73 | MAPT (0.57) | GAAMAPTMEN1KMT2AALDH1A1 | |
| SCHEMBL22689687 | 0.73 | SLC7A5 (0.56) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL12835439 | 0.73 | ALDH1A1 (0.56) | MAPTMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL16860980 | 0.73 | SLC7A5 (0.56) | MAPTMEN1KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421887-B1 | METHOD FOR THE MANUFACTURE OF DEGARELIX | POLYPEPTIDE LABORATORIES AS (DK) | 2015-04-22 | — | — | EP | claimed |
| US-8828938-B2 | Method for the manufacture of degarelix | POLYPEPTIDE LABORATORIES A/S (DK) | 2014-09-09 | — | — | US | claimed |
| EP-2421887-A1 | METHOD FOR THE MANUFACTURE OF DEGARELIX | Polypeptide Laboratories A/S (DK) | 2012-02-29 | — | — | EP | claimed |
| US-20120041172-A1 | METHOD FOR THE MANUFACTURE OF DEGARELIX | POLYPEPTIDE LABORATORIES A/S (DK) | 2012-02-16 | — | — | US | claimed |
| WO-2010121835-A1 | METHOD FOR THE MANUFACTURE OF DEGARELIX | POLYPEPTIDE LABORATORIES A/S (DK) | 2010-10-28 | — | — | WO | claimed |
| EP-3981781-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | Fresenius Kabi iPSUM S.r.l. (IT) | 2022-04-13 | — | — | EP | disclosed |
| CN-109575109-B | Method for preparing degarelix by fragment condensation | 兰州大学 | 2022-03-25 | — | — | CN | disclosed |
| US-20220033443-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | Fresenius Kabi iPSUM S.r.l (IT) | 2022-02-03 | — | — | US | disclosed |
| US-11168114-B2 | Process for the manufacture of degarelix and its intermediates | Fresenius Kabi iPSUM S.r.l (IT) | 2021-11-09 | — | — | US | disclosed |
| US-20200172577-A9 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | Fresenius Kabi Ipsum S.R.L. (IT) | 2020-06-04 | — | — | US | disclosed |
| US-20180362588-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | FRESENIUS KABI IPSUM S R L (IT) | 2018-12-20 | — | — | US | disclosed |
| EP-3390427-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | Fresenius Kabi iPSUM S.r.l. (IT) | 2018-10-24 | — | — | EP | disclosed |
| US-8828938-B2 | Method for the manufacture of degarelix | POLYPEPTIDE LABORATORIES A/S (DK) | 2014-09-09 | — | — | US | disclosed |
| CN-102428097-A | Method for producing degarelix | POLYPEPTIDE LABORATORIES AS (DK) | 2012-04-25 | — | — | CN | disclosed |
| EP-2421887-A1 | METHOD FOR THE MANUFACTURE OF DEGARELIX | Polypeptide Laboratories A/S (DK) | 2012-02-29 | — | — | EP | disclosed |
| EP-2421887-A1 | METHOD FOR THE MANUFACTURE OF DEGARELIX | Polypeptide Laboratories A/S (DK) | 2012-02-29 | — | — | EP | disclosed |
| US-20120041172-A1 | METHOD FOR THE MANUFACTURE OF DEGARELIX | POLYPEPTIDE LABORATORIES A/S (DK) | 2012-02-16 | — | — | US | disclosed |
| US-20120041172-A1 | METHOD FOR THE MANUFACTURE OF DEGARELIX | POLYPEPTIDE LABORATORIES A/S (DK) | 2012-02-16 | — | — | US | disclosed |
| WO-2010121835-A1 | METHOD FOR THE MANUFACTURE OF DEGARELIX | POLYPEPTIDE LABORATORIES A/S (DK) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010121835-A1 | METHOD FOR THE MANUFACTURE OF DEGARELIX | POLYPEPTIDE LABORATORIES A/S (DK) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168114-B2 | Process for the manufacture of degarelix and its intermediates | ANPEP, DNPEP, NPPA | GAA 173/4885MAPT 3248/4885MEN1 2301/4885 |
| US-20120041172-A1 | METHOD FOR THE MANUFACTURE OF DEGARELIX | DNPEP, PEPD, VIP | GAA 266/4885MAPT 3710/4885MEN1 3458/4885 |
| US-20220033443-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | ANPEP, DNPEP, NPPA | GAA 173/4885MAPT 3248/4885MEN1 2301/4885 |
| US-20200172577-A9 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | ANPEP, DNPEP, NPPA | GAA 173/4885MAPT 3248/4885MEN1 2301/4885 |
| US-20180362588-A1 | PROCESS FOR THE MANUFACTURE OF DEGARELIX AND ITS INTERMEDIATES | ANPEP, DNPEP, NPPA | GAA 173/4885MAPT 3248/4885MEN1 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.